Complexity and clinical significance of drug–drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT)

Nikolaos Tsoukalas1,2 · Norman Brito-Dellan3 · Carme Font4 · Taylor Butler5 · Cristhiam M. Rojas-Hernandez6 · Thomas Butler7 · Carmen Escalante8 · on behalf of the MASCC Hemostasis Study Group

Received: 19 January 2022 / Accepted: 14 June 2022 / Published online: 6 August 2022
© The Author(s) 2022, corrected publication 2022

Abstract
Cancer patients have an increased risk of developing venous thromboembolic events. Anticoagulation management includes prophylactic or therapeutic doses of low molecular weight heparins (LMWHs) or direct oral anticoagulants (DOACs). However, the management of thrombosis in patients with cancer is complex due to various individual and disease-related factors, including drug–drug interactions (DDIs). Furthermore, DDIs may impact both, cancer and venous thrombosis, treatment effectiveness and safety; their relevance is highlighted by the advances in cancer therapeutics. Given that these new oncology drugs are extensively used, more attention should be given to monitoring potential DDIs to minimize risks. Recognition of DDIs is of utmost importance in an era of rapid developments in cancer treatments and introduction of novel treatments and protocols. When managing cancer-associated thrombosis (CAT), the concomitant use of a DOAC and a moderate or strong modulator (inhibitor or inducer) of CYP3A4 or a P-glycoprotein (P-gp) is most likely to be associated with significant DDIs. Therefore, LMWHs remain the first-line option for the long-term management of CAT under these circumstances and physicians must consider utilizing LMWHs as first line. This review describes the risk of DDIs and their potential impact and outcomes in patients with cancer associated thrombosis (CAT) receiving anticoagulation.

Keywords Drug-Drug Interactions (DDIs) · Cancer-Associated Thrombosis (CAT) · Oncology · Anticoagulant · Bleeding · Low Molecular Weight Heparins (LMWHs) · Direct Oral Anticoagulants (DOACs)

Introduction
Patients with active cancer have a four- to sevenfold increased risk of experiencing venous thromboembolism (VTE), which includes both deep-vein thrombosis (DVT) and pulmonary embolism (PE) [1, 2]. Anticoagulation is the cornerstone of VTE management regardless of cancer status. Various professional guidelines recommend the use of either low molecular weight heparins (LMWHs, e.g., dalteparin, enoxaparin, tinzaparin, bemiparin) or oral anticoagulants including vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs, e.g., apixaban, edoxaban, rivaroxaban) [3–5]. However, potential drug–drug interactions (DDIs) should be considered before initiating anticoagulation and reviewed periodically during follow-up.

The purpose of this narrative review is to describe the main DDIs mechanisms that challenge clinicians for the
proper management of the patient regarding cancer associated thrombosis (CAT). We summarize the most relevant evidence currently available in this topic, focusing on practical daily care situations in oncology.

**General Mechanisms of Potential Drug–Drug Interactions (DDIs)**

There are several types of DDIs: pharmacodynamic DDIs, pharmacokinetic DDIs, drug transporters DDIs, human plasma protein DDIs, and absorption DDIs (Table 1).

- Pharmacodynamic interactions may be the ones with the most severe repercussions. These DDIs are the product of the additive effects of the two associated drugs, resulting in therapeutic effects or toxicities when mixed with other drugs or due to an additive effect with mutual potentiation of toxic effects.
- There are several types of pharmacokinetic interactions. The main type is involving drug metabolism by the cytochrome P450 (CYP) enzyme system. Other types are pharmacokinetic interaction concern drug transporters, human plasma protein and absorption.

| Type of DDIs                        | Main proteins involved | Mechanisms                                                                 |
|------------------------------------|------------------------|-----------------------------------------------------------------------------|
| Pharmacodynamic interactions       |                        | Additive effects of the two drugs                                           |
| Drug transporter DDIs               | BCRP, OATP, OCT, MATE, OATP, P-gp | Inhibition of the transporter leads to a higher drug blood concentration |
|                                    |                        | Induction of the transporter leads to a lower drug blood concentration     |
| Pharmacokinetic interactions        | CYP3A4 (mainly), CYP2C9,… | Inhibition of the CYP3A4 leads to a higher drug blood concentration          |
|                                    |                        | Induction of the CYP3A4 leads to a lower drug blood concentration           |
| Human plasma protein DDIs           | Albumin, alpha 1-glycoprotein | Competition on the binding site of a protein carrier change the drug concentration because only the free drug is active |
| Absorption DDIs                    |                        | Intragastric pH influences the solubility and bioavailability of drugs      |

- Drug transporter-related DDIs are also common. If two drugs are substrates of the same transporter, competition may result in a reduced transport of one drug, or both drugs. Furthermore, the co-administration of an inhibitor of the transport with a substrate of the same transport may lead to increase of the substrate blood level, leading to potential adverse events. Finally, the co-administration of an inducer of the transport with a substrate of the same transport may lead to decrease of the substrate blood level, leading to potential inefficacy. During the metabolization phase, drug transporters like P-gp and BCRP play a significant role. Other drug efflux transporters that may influence bioavailability drugs are the multidrug resistance protein subfamily (ATP-binding cassette subfamily C member 1 to 12, ABCC1 to 12, like MRP1) and the multi-antimicrobial extrusion protein (MATE), while several uptake transporters may be involved as well [e.g., organic anion transporting peptides (OATPs), organic anion transporters (OATs), and organic cation transporters (OCTs)] [7].

It is also important to mention that inhibitors/inducers of CYP isoenzymes are more and more described as weak, moderate and strong. However, it is not always clear to understand the meaning of this classification. According to the EMA, enzyme inhibitors may be classified based on their potency. A strong inhibitor causes a > fivefold increase in the plasma AUC values or ≥ 80% decrease in oral clearance, a moderate inhibitor causes a > twofold increase in the plasma AUC or 50% ≤ inhibition of oral clearance, and a mild inhibi-
Pharmacodynamic DDIs

Pharmacodynamic DDIs are linked to all anticoagulants, and they are not so easy to anticipate even though they are common.

One study included patients with advanced cancer treated with concurrent VEGFR TKIs and factor Xa inhibitors [11]. Perturbation of the tumor-associated endothelial cells (and potentially non-cancerous tissue) and disturbance of platelet function by VEGFR TKIs may modulate the activation of the coagulation cascade, leading to both bleeding and thromboembolic risks. The authors reported that among 86 cancer patients mainly treated with LMWHs, DOACs, or LMWHs plus DOACs, there was a higher overall bleeding rate in patients anticoagulated and concomitant use of VEGFR-TKIs compared to patients who were receiving only anticoagulants (HR 2.45 [1.28-1.69]). A sub-analysis demonstrated that this higher rate of bleeding was not significant when comparing LMWHs vs. LMWHs plus VEGFR TKI (HR 1.85 [0.90-3.81]) and when investigating DOACs vs. DOACs plus VEGFR TKI (HR 4.16 [0.38-45.00]). Besides the fact that the HR was higher with DOACs, suggesting a possible higher risk of bleeding with DOACs for the entire follow-up period (around 30 months), the 6-months analysis reported a higher significant risk of bleeding in the LMWHs group.

Pharmacokinetic DDIs and Drug Transporter DDIs

One crucial difference between LMWHs and DOACs is their metabolism and pharmacokinetic parameters (Table 2) [12]. Indeed, the metabolism of DOACs includes CYP3A4 and P-glycoprotein (P-gp). However, it is not the case for LMWHs as their metabolism does not involve CYP3A4 and P-gp [12].

Consequently, a potentially important safety consideration in using any DOACs in CAT is the risk for DDIs with systemic anticancer treatments, including chemotherapeutic agents, hormonal therapy, immunotherapy, and drugs used in supportive care like dexamethasone or antiemetic drugs. Potent inhibitors or inducers of P-gp and potent inhibitors or inducers of cytochrome CYP3A4 can interact with DOACs [5, 12] and many anticancer drugs are substrate, inhibitor, and/or inducer of the CYP3A4 and P-gp [13]. Additional clinically significant DDIs data may emerge over time [14].

It must be taken into account that drugs with strong DDIs potential were excluded in DOACs trials for CAT, including drugs commonly used in cancer treatment and supportive care. Regular clinical practice requires understanding and careful assessment of patients who are exposed to these drugs. The clinical impact of such DDIs with strong CYP3A4/P-gp inhibitors was described in a retrospective study concluded that among patients receiving DOACs, concurrent use of clarithromycin was associated with a significantly greater risk of hospital admission with significant bleeding [15].

It is also essential to consider that both moderate inhibitors of CYP3A4/P-gp and not only the strong ones can impact the bleeding rate in VTE patients. Hanigan et al. reported that DDIs led to significantly more bleeding in an atrial fibrillation (AFib) population treated with apixaban or rivaroxaban. The same publication reported that the increased risk of bleeding started shortly after the exposure to a DDI and increased over time [16]. Another study [17] reported that apixaban in AFib patients exposed to CYP3A4 and/or P-gp inhibitors also had an increased risk for severe bleeding (HR 1.23; 1.01–1.5), whereas a significant effect for patients treated with rivaroxaban or dabigatran and these interacting drugs could not be established (rivaroxaban, HR 1.24; 0.94–1.65, and dabigatran HR 0.84; 0.48–1.45).

Interestingly, the TacDOAC registry [18] reported the bleeding rates among 202 cancer patients treated with DOACs (mainly apixaban and rivaroxaban) and receiving anticancer targeted therapies (Tables 3 and 4). Bleeding rates were analyzed according to the class of anticancer drugs. Several of the anticancer drugs were weak or moderate inhibitors of CYP3A4 with or without P-gp inhibition.
properties. Major bleeding (MB) rates ranged from 2.3% to 9.5%, and clinically relevant non-major bleeding (CRNMB) rates ranged from 2.3% to 14.3%. These data should be interpreted with caution, as there was no control group. However, when looking at the SELECT-D (rivaroxaban) and CARAVAGGIO/ADAM VTE (apixaban) trials, the TacDOAC bleeding rates seemed higher than the bleeding rates of those 3 RCTs. The authors concluded that concomitant use of different targeted anticancer therapies with DOACs resulted in different bleeding risks, with Bruton’s tyrosine kinase (BTK) inhibitors and vascular endothelial growth factor (VEGF) inhibitors found to be associated with higher risks.

The potential mechanism of interactions described also includes weak inhibitors or inducers of the CYP3A4/P-gp [18, 19], adding more complexity to this topic. Based on the Hanigan and the TacDOAC results, it seems vital to be cautious with weak and moderate CYP3A4/P-gp inhibitors when prescribing a DOAC. Although, in these two studies were not included patients who received LMWHs, we should keep in mind that LMWHs in contrast to DOACs are not getting metabolized through CYP3A4/P-gp.

Several case reports describing DDIs between CYP3A4/P-gp inhibitors (or inducers) have been reported involving many different drug classes [20], including antivirals, antibiotics, antifungals, dexamethasone, etc., even with low doses of DOACs [21]. Therefore, there is a need to check all the drugs and not only the anticancer drugs for potential DDIs even when DOACs are utilized at a low dose.

The data on DDIs in patients with CAT are scarce. Most of the studies and cases described below included non-cancer patients with AFib or thrombosis. However, there are a few published CAT cases. Serrao A et al. [22] reported two cases of cancer patients who developed bleeding complications after receiving azacitidine and apixaban or dabigatran. Burden T et al. [23] described the case of a breast cancer patient who sustained a DDI with carbamazepine after switching from a LMWH to rivaroxaban.

It is also important to mention that DDI risk is also including other type of drugs, such as pain killer, selective serotonin reuptake inhibitors (SSRI), and antiemetics. Indeed, several of these agents are well-known substrates and/or inhibitors or CYP3A4 and/or P-gp, such as fluoxetine, paroxetine, sertraline, fentanyl, aprepitant, and fosaprepitant [13, 24].

Finally, the DDI between DOACs and other drugs involving the BCRP are still not clear. However, LMWHs do not interact with BCRP. One in vitro study confirmed that BCRP was involved in DOACs’ disposition [25]. The same team reported that BCRP-mediated transport of apixaban and rivaroxaban was inhibited by 36% and 77%, respectively, in another in vitro study. Nevertheless, the authors also concluded that it was unlikely that a clinically significant DDIs would occur in vivo [26]. Because there are no published clinical data or case report on a potential clinically relevant

| Anticoagulant | Target | Protein Binding |
|---------------|--------|-----------------|
| LMWH         | -      | -               |
| Rivaroxaban   | AntXa  | 95%             |
| Apixaban      | AntiXa | 87%             |
| Edoxaban      | AntiXa | 42.5%           |

Table 2: Main pharmacokinetic characteristics of anticoagulants [12]
DDIs involving BCRP, it is hard to make a definitive conclusion about potential DDIs with BCRP substrates, inhibitors, or inducers.

Most of the pharmacokinetic DDIs pertain the risk of CYP3A4 and/or P-gp inhibition. However, there is also a risk with CYP3A4 and/or P-gp inducers to consider.

Several studies investigated the risk of inducing the metabolism when receiving DOACs. Sennesael AL et al. [27] included 17 non-cancer patients mainly receiving apixaban with an inducer as a co-medication (carbamazepine, phenobarbital, phenytoin, or rifampicin). The result suggested a significant risk of reduced DOAC blood levels in patients taking strong P-gp and CYP3A4 inducers, including those without risk factors for drug accumulation. The authors reported that some actions were necessary during the follow-up for several patients, including dose increase and switch to other anticoagulants. Perlman A. et al. [28] also investigated the management of hospitalized patients with DOACs and co-administration of inducers. The authors reported that the concentration of DOACs was measured in 11 patients (10 received apixaban and one rivaroxaban) with enzyme inducers. Among apixaban-treated patients, 5 (50%) had concentrations below the 5th percentile of standard-dose apixaban in the ARISTOTLE study population. In the rivaroxaban-treated patients, the concentration measured was below the 5th percentile of rivaroxaban in the ROCKET-AF study population. It is important to notice that DOACs were used for AFib in non-cancer patients and not for CAT. Identifying this interaction led to monitoring DOACs concentration in 50% of the patients and by modifying treatment in 55% of the patients.

The drug–drug interactions between DOACs and other drugs involving human plasma proteins are still not precise. However, LMWHs do not interact with human plasma proteins.

In humans, DOACs are bound to human plasma proteins, primarily to serum albumin, the most abundant human plasma protein. The molar fractions of apixaban, edoxaban, and rivaroxaban bound to human plasma proteins are 87%, 35%, 55%, and 95%, respectively [29]. LMWHs, in contrast, have low human plasma protein binding [30]. However, there is no study evaluating the potential impact of human plasma protein DDIs in thrombosis. Indeed, only few cases were reported over times with no clear evidence of clinical outcomes [12, 31]. As a consequence, it seems to be more a theoretical risk in thrombosis, but it is also important to consider the profile of the patients and more importantly the renal function and the nutrition status [32, 33].

**Food–Drug Interactions and Over the Counter Drugs**

Food–drug interactions (FDIs) do not have the same level of concern among the medical community as DDIs. However, there are also some FDIs to consider in CAT patients. The intestinal metabolic enzyme CYP3A4 exerts its action in the proximity of P-gp in the enterocytes of the gut lumen. Simultaneous use of substrates for intestinal CYP3A4 and CYP3A4 inhibitors and inducers can change the exposure and toxicity of these drugs. For example, the area under the curve of sunitinib and nilotinib was increased by 11% and 29%, respectively, because of grapefruit, a well-known CYP3A4 inhibitor [31] (Tables 3 and 4). Some many other foods or herbs may potentially influence the pharmacokinetic parameters of oral anticoagulants. Orange, grapefruit, eucalyptus, garlic, grape juice, licorice, peppermint are the best-known herbs and foods that inhibit CYP3A4 [34]. Ginkgo biloba, berberine, green tea, grape juice, curcumin are also inhibitors of the P-gp [34]. In theory, there is a potential risk of bio-accumulation of anticoagulants substrates of CYP3A4 and/or P-gp in case of consumptions of such aliments. However, the clinical consequences are unknown.

Dietary supplements are commonly used. One survey [35] reported that 89.6% of the patients had at least an occasional use of one or more dietary supplements; 78.1% reported daily use of at least one dietary supplement. The most taken dietary supplements with potential apixaban interactions and increased bleeding risk were herbal teas (11.1%) and turmeric (9%). Chinese herbs, ginger, and ginkgo biloba were used in fewer than 5% of respondents. Use of St John's wort was rare (<1%).

Although food or herbal inhibitors of CYP3A4/P-gp might interfere with the pharmacokinetics of DOACs, no direct evidence of such interactions was reported [34]. However, it highlights the complexity of the topic and the uncertainty around DDIs. Indeed, the clinical consequences of the use of a weak inhibitor of CYP3A4 and a cup of green tea and grapefruit juice in the morning was not explored.

It is also important not to focus only on potential DDIs between anticoagulants and prescribed drugs but also to consider over the counter (OTC) drugs. Tar and colleagues reported that 33% of patients had at least one OTC product with potentially serious apixaban interactions daily/most day and 6.7% took multiple products [35]. The publication did not report the clinical outcomes, but it highlighted the need to consider DDIs between DOACs and every drug, including OTC, for which the physicians have low control and may not be aware. Consequently, there is a need to routinely ask patients for any use of medications such as antiplatelets, NSAIDs.

The main challenge with food, herbs, diet supplements is the complexity of checking their usage regularly and the need to communicate updated information for each patient with different health care providers involved in the care of patients with CAT patients.
| Cancer type                                                                 | Anticancer drugs | CYP3A4 interactions | P-gp interactions | BCRP interaction | Protein binding |
|----------------------------------------------------------------------------|------------------|---------------------|-------------------|------------------|-----------------|
| Anal, Biliary, Head&Neck, Breast, Cervical, Colorectal, Oesophagus, Gastric, NETs, Pancreas | 5-FU             | No                  | No                | No               | No              |
| Prostate                                                                   | Abiraterone      | Moderate inhibitor  | Strong inhibitor  | No               | 99.8%           |
| Lymphoma                                                                   | Acalabrutinib    | Weak inhibitor      | Substrate         | Substrate        | 97.5%           |
| Ewing, Osteosarcoma, Sarcomas                                              | Actinomycin-D    | No                  | No                | No               | No              |
| Lung                                                                       | Afatinib         | No                  | Inhibitor         | Substrate and inhibitor | 95%        |
| Colorectal                                                                 | Aflibercept      | No                  | No                | No               | No              |
| Lung                                                                       | Alectinib        | No                  | No                | Inhibitor and substrate (M4) | No        |
| Breast                                                                     | Anastrozole      | Weak/moderate inhibitor | No             | No               | Not highly      |
| Bladder, Lung                                                              | Atezolizumab     | No                  | No                | No               | No              |
| Bladder                                                                    | Avelumab         | No                  | No                | No               | No              |
| Kidney                                                                     | Axitinib         | Substrate           | No                | Substrate        | >99%            |
| Brain, Breast, Cervical, Colorectal, Kidney, Lung, Mesothelioma, Ovarian | Bevacizumab      | No                  | No                | No               | No              |
| Melanoma                                                                   | Binimetinib      | No                  | Substrate         | Substrate        | 97.2%           |
| Testicular, Osteosarcoma                                                   | Bleomycin        | No                  | No                | Inhibitor        | Limited extend  |
| Lung                                                                       | Brigatinib       | Inducer and substrate | Substrate     | Substrate        | 91%             |
| Prostate                                                                   | Cabazitaxel      | No                  | Inhibitor         | Inhibitor        | 89-92%          |
| Kidney, Thyroid                                                            | Cabozantinib     | Weak inhibitor and substrate | Inhibitor and substrate | Inhibitor | 99.7%           |
| Anal, Cervical, Colorectal, CUP, Biliary, Breast, Oesophagus, Gastric, Pancreas, Thymoma | Capecitabine | No                  | No                | No               | 10-62%          |
| Biliary, Bladder, Breast, Cervical, CUP, Oesophagus, Gastric, Head&Neck, Lung, Melanoma, Mesothelioma, Osteosarcoma, Ovarian, Pancreas, Testicular, Thymoma, Uterus, Prostate | Carboplatin     | No                  | No                | No               | 29-90%          |
| Brain                                                                       | Carmustine       | No                  | No                | No               | No              |
| Lung                                                                       | Ceritinib        | Weak/strong inhibitor | Substrate   | Inhibitor        | 97%             |
| Colorectal, Head&Neck                                                      | Cetuximab        | No                  | No                | No               | No              |
| Anal, Biliary, Bladder, Breast, Cervical, CUP, Oesophagus, Gastric Head&Neck, Liver, Lung, Melanoma, Mesothelioma, NETs, Osteosarcoma, Ovarian, Pancreas, Prostate, Testicular, Thymoma, Thyroid, Uterus | Cisplatin | No                  | No                | No               | 90%             |
| Melanoma                                                                   | Cobimetinib      | Substrate           | Substrate         | Inhibitor        | 94.8%           |
| Lung                                                                       | Crizotinib       | Moderate inhibitor and substrate | Strong inhibitor and substrate | No             | 91%             |
| Cancer type                                                                 | Anticancer drugs                                                                 | CYP3A4 interactions                          | P-gp interactions | BCRP interaction | Protein binding |
|----------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------------------------------------|-------------------|------------------|-----------------|
| Bladder, Breast, Cervical, Ewing, Head&Neck, Lung, Sarcomas, Thymoma, Osteosarcoma, Ovarian | Cyclophosphamide                                                                | Weak inhibitor/inducer and substrate         | No                | No               | 20-70%          |
| Lung, Melanoma                                                             | Dabrafenib                                                                      | Moderate inducer/substrate transient inhibitor and substrate | Substrate         | Inhibitor and substrate | 99.7%           |
| Melanoma, Sarcomas                                                         | Dacarbazine                                                                     | No                                           | No                | No               | 5%              |
| Bladder, Breast, Cervical, Ewing, Head&Neck, Lung, Sarcomas, Prostate, Thyroid, Uterus | Doxorubicin                                                                      | Weak inhibitor and substrate                 | Inducer / strong inhibitor and substrate | No               | 70%             |
| Lung, CUP, Head&Neck, Pancreas, Oesophagus, Gastric, Lung, Ovarian, Prostate, Sarcomas | Durvalumab                                                                      | No                                           | No                | No               | No              |
| Prostate                                                                   | Encorafenib                                                                     | Inhibitor/inducer and substrate              | Inhibitor and substrate | Inhibitor         | 86.1%           |
| Bladder, Breast, Cervical, Ewing, Head&Neck, Lung, Sarcomas, Prostate, Thyroid, Uterus | Enzalutamide                                                                    | Strong inducer and substrate                | Strong inducer and substrate | Substrate (M5) | >99%            |
| Breast, Sarcomas                                                           | Eribulin                                                                        | No                                           | No                | No               | 49-65%          |
| Lung, Pancreas                                                             | Erlotinib                                                                       | Inhibitor and substrate                     | Inhibitor and substrate | Substrate | 95%             |
| Prostate                                                                   | Estramustine                                                                    | No                                           | Inhibitor         | No               | No              |
| CUP, Ewing, Lung, NETs, Osteosarcoma, Ovarian, Prostate, Thyroid, Fluorescein | Etoposide                                                                       | Inducer/weak inhibitor                      | Inhibitor         | No               | 97%             |
| Breast, Kidney, NETs                                                       | Everolimus                                                                       | Weak inhibitor and substrate                 | Inhibitor and substrate | No               | 74%             |
| Breast                                                                     | Exemestane                                                                      | Substrate                                    | No                | No               | 90%             |
| Melanoma                                                                   | Fotemustine                                                                     | No                                           | No                | No               | 25-30%          |
| Breast                                                                     | Fulvestrant                                                                     | Substrate                                    | No                | No               | 99%             |
| Lung                                                                       | Gefitinib                                                                       | Inhibitor and substrate                     | Inhibitor and substrate | Inhibitor | 90%             |
| Biliary, Bladder, Breast, Cervical, CUP, Kidney, Liver, Lung, Ovarian, Prostate, Sarcomas, Testicular, Thyroid, Uterus | Gemcitabine                                                                     | No                                           | No                | No               | No              |
| Head&Neck                                                                  | Hydroxyurea                                                                     | No                                           | No                | No               | No              |
| Lung                                                                       | Ibrutinib                                                                       | Weak inhibitor and substrate                 | Inhibitor and substrate | Inhibitor | 97.3%           |
| Cervical, Ewing, Head&Neck, Kidney, Lung, Osteosarcoma, Sarcomas, Testicular, Thyroid, Uterus | Ifosfamide                                                                      | Weak inhibitor and substrate                 | No                | No               | N/A             |
| Cancer type                                                                 | Anticancer drugs | CYP3A4 interactions                      | P-gp interactions | BCRP interaction | Protein binding |
|---------------------------------------------------------------------------|------------------|------------------------------------------|-------------------|------------------|-----------------|
| GIST                                                                      | Imatinib         | Moderate inhibitor and substrate         | Strong inhibitor and substrate | Inhibitor and substrate | 95%             |
| Kidney, Liver, Melanoma, NETs                                            | Interferons      | No                                       | No                | No               | No              |
| Melanoma                                                                  | Ipilimumab       | No                                       | No                | N/A              | N/A             |
| Brain, Colorectal, CUP, Oesophagus, Gastric, Ovarian, Pancreas, Testicular, Thymoma | Irinotecan       | Substrate                                | Substrate         | No               | 65-95%          |
| NETs                                                                      | Lanreotide       | Inhibitor                                | No                | No               | No              |
| Breast                                                                    | Lapatinib        | Weak-mild inhibitor and substrate        | Moderate-strong inhibitor and substrate | Inhibitor and substrate | >99%            |
| Kidney, Liver, Thyroid                                                   | Lenvatinib       | Weak inducer/weak inhibitor              | Substrate         | Substrate        | 98-99%          |
| Breast                                                                    | Letrozole        | Substrate                                | No                | No               | 60%             |
| Brain                                                                     | Lomustine        | Mild inhibitor                           | No                | No               | No              |
| Breast, Uterus                                                            | Megestrol acetate| No                                       | No                | No               | No              |
| Ewing, Osteosarcoma, Sarcomas, Testicular                                 | Mesna            | No                                       | No                | No               | No              |
| Bladder, Breast, Head&Neck, Osteosarcoma, Testicular                      | Methotrexate     | No                                       | Substrate         | Substrate        | 50%             |
| Osteosarcoma                                                              | Mifamurtide      | No                                       | No                | No               | No              |
| Anal                                                                      | Mitomycin        | No                                       | Substrate         | No               | No              |
| Prostate                                                                  | Mitoxantrone     | No                                       | No                | Substrate        | 78%             |
| Lung                                                                      | Mocobertinib     | N/A                                      | N/A               | N/A              | N/A             |
| Breast, Lung, Pancreas                                                   | Nab-paclitaxel   | Moderate inducer and substrate            | Inhibitor and substrate | No              | No              |
| Breast                                                                    | Neratinib        | Substrate                                | Substrate and inhibitor | Inhibitor        | 98-99%          |
| CML                                                                       | Nilotinib        | Moderate inhibitor and substrate          | Inhibitor and substrate | Inhibitor        | 98%             |
| Head&Neck, Lung                                                           | Nintedanib       | No                                       | Strong inhibitor and substrate | No              | 97.8%           |
| Bladder, Colorectal, Gastric, Head&Neck, Liver, Oesophagus, Melanoma     | Nivolumab        | No                                       | No                | No               | No              |
| Thymoma, NETs                                                             | Octreotide       | No                                       | No                | No               | 65%             |
| Breast, Ovarian, Prostate                                                 | Olaparib         | Weak inhibitor and substrate              | No                | Inhibitor        | 70-91%          |
| Sarcomas                                                                  | Olaratumab       | No                                       | No                | No               | No              |
| Lung                                                                      | Osimertinib      | Weak inhibitor and substrate              | Inhibitor and substrate | Inhibitor        | 94.7%           |
| Anal, Biliary, Colorectal, CUP, Oesophagus, Gastric, Liver, Ovarian, Pancreas, Testicular | Oxaliplatin     | No                                       | No                | No               | No              |
| Cancer type | Anticancer drugs | CYP3A4 interactions | P-gp interactions | BCRP interaction | Protein binding |
|-------------|------------------|---------------------|-------------------|------------------|-----------------|
| Biliary, Bladder, Breast, Cervical, CUP, Gastric, Head&Neck, Lung, Melanoma, Oesophagus, Ovarian, Sarcomas, Testicular, Thyroid, Thymoma, Uterus | Paclitaxel | Moderate inducer and substrate | Inhibitor and substrate | No | 94% |
| Breast | Palbociclib | Weak inhibitor and substrate | Inhibitor and substrate | Inhibitor | 85% |
| Colorectal | Panitumumab | No | No | No | No |
| Kidney, Sarcomas | Pazopanib | Weak inhibitor | Moderate inhibitor substrate | Substrate | 99% |
| Bladder, Breast, Colorectal, Gastric, Head&Neck, Liver, Lung, Melanoma, Mesothelioma, Oesophagus | Pembrolizumab | No | No | No | No |
| Lung, Mesothelioma | Pemetrexed | No | No | No | 81% |
| Breast | Pertuzumab | No | No | No | No |
| Brain | Procarbazine | No | No | No | No |
| Prostate | Radium 223 | No | No | No | No |
| Mesothelioma | Ramucirumab | No | No | No | No |
| Colorectal, Gastric | Regorafenib | Inhibitor and substrate | Inhibitor and substrate | Inhibitor | >99% |
| Colorectal, GIST, Liver | Rucaparib | Weak inhibitor and substrate | Inhibitor and substrate | Substrate and weak inhibitor | 70.2% |
| Ovarian | S-1 (Tegafur, gimeracil, oteracil) | No | No | No | 52% (Tegafur) |
| Gastric | Sonidegib | Substrate | No | Inhibitor | >97% |
| Skin | Sorafenib | Inhibitor and substrate | Inhibitor and substrate | No | 99% |
| GIST, Kidney, Liver, Melanoma, Thyroid | Streptozocin | N/A | N/A | N/A | N/A |
| NETs | Sunitinib | Inhibitor and substrate | Inhibitor and substrate | No | 90-95% |
| GIST, Kidney, NETs, Thyroid, Thyroid | Temozolomide | Mild inhibitor/inducer and substrate | Strong inhibitor / inducer | No | >99% |
| Breast, Ovarian | Temsirolimus | Mild inhibitor | Inhibitor | No | 10-20% |
| Brain, Melanoma | Topotecan | Inhibitor/inducer | Inhibitor | No | 35% |
| Kidney | Temozolomide | Weak-mild inhibitor and substrate | Inhibitor and substrate | No | 40-85% |
| Cervical, Lung, Ovarian | Trabectedin | Substrate | Substrate | No | 94-97% |
| Ovarian, Sarcomas | Tranetinib | Inducer | Inhibitor and substrate | Transient inhibitor | 97.4% |
| Lung, Melanoma | Tremelimumab | No | No | No | No |
| Breast, Gastric | Trastuzumab | No | No | No | No |
| Breast | Trastuzumab emtansine | No | No | No | No |
| Mesothelioma | Trastuzumab | No | No | No | No |
| Colorectal | Trametinib | No | No | No | No |
| Colorectal | UFT (Tegafur/uracil) | No | No | No | No |
| Thyroid | Vandetanib | Substrate | Strong inhibitor | Inhibitor | 90-94% |
Several factors are associated with the development of DDIs, and most of them usually coexist in the oncological patients, including the following:

(i) Cancer and older age: DDIs are a growing concern in medicine and more specifically in cancer [36]. Leeuwen R.W. et al. [37] reported that 46% of cancer patients were exposed to at least one DDI. Furthermore, 14% of these DDIs were life-threatening or leading to permanent damage, and 84% of these DDIs led to the deterioration of a patient's status requiring treatment, highlighting the clinical impact of DDIs in cancer. Lechat P et al. [38] reported that 89.5% of elderly patients were exposed to at least one DDI. Most of these DDIs were classified as "highly clinically significant, avoid combination," or "moderately clinically significant, usually avoid combination." The latter study reported the clinical importance of DDIs in the general elderly population. In the studies mentioned above by Leeuwen and Lechat, older patients with cancer are at risk of DDIs.

(ii) Polypharmacy: is also a significant risk factor for DDIs [39]. Polypharmacy is common in cancer patients [40] and also in thrombosis [41]. Furthermore, there is a close relationship between polypharmacy and DDIs. One study [42] reported that the risk of major DDIs in cancer patients increased from 14% in patients receiving less than four medications to 24% in those receiving 4 to 7 medications and to 40% with 8 to 11 medications and finally to 67% in patients receiving more than 11 medications. The authors reported that the severity of DDIs was a significant and clinically relevant prognostic factor in advanced breast cancer [43]. Although there is a lack of data about polypharmacy in CAT patients, these patients would likely be also exposed to polypharmacy. Notably, one single patient might be exposed to several concomitant DDIs. In this regard, it is difficult to estimate the final effect. Indeed, the clinical impact of two moderate CYP3A4 inhibitors or two weak and one moderate CYP3A4 inhibitors in not clear. However, such might not be rare because the IPOP study reported that among 924 elderly non-cancer patients, 77.0% of them were exposed to at least two DDIs [38].

(iii) Patient's profile regarding comorbidities and organs' dysfunction: is also of great relevance. One pharmacokinetic study reported increased area under the curve of rivaroxaban in patients with mild renal impairment exposed to verapamil [44]. Patients with cancer are at increased risk of renal impairment, and around 50% of cancer patients are exposed to renal insufficiency [45]. Mild renal impairment is not enough to induce bioaccumulation of rivaroxaban, but this study highlights that the combination of several bioaccumulative risk factors could influence the pharmacokinetics of a drug. Gong IY et al. [46] also reported that moderate hepatic impairment, renal impairment, ethnicity, weight, and age could influence the pharmacokinetic of DOACs.

(iv) Pharmacological characteristics of the drugs: have a significant impact on the risk and characteristics of the DDIs. In general, a lower risk is associated with monoclonal antibodies and a higher risk with

Table 3 (continued)

| Cancer type | Anticancer drugs | CYP3A4 interactions | P-gp interactions | BCRP interaction | Protein binding |
|-------------|------------------|---------------------|-------------------|-----------------|----------------|
| Lung, Melanoma | Vemurafenib | Moderate inducer and substrate | Inhibitor and substrate | Inhibitor and substrate | 99% |
| Bladder, Melanoma, Testicular | Vinblastine | Weak inhibitor/inducer and substrate | Strong inducer and substrate | No | No |
| Brain, Ewing, Lung, Sarcomas, Thymoma | Vincristine | Mild inhibitor/inducer and substrate | Inducer/Inhibitor and substrate | No | 75% |
| Melanoma | Vindesine | Substrate | No | Inhibitor | No |
| Bladder | Vinflunine | Substrate | No | No | 67.2% |
| Breast, Cervical, Lung, Ovarian, Prostate, Sarcomas Mesothelioma | Vinorelbine | Weak inhibitor and substrate | No | No | 13.5% |
| Basal cell carcinoma | Vismodegib | No | No | Inhibitor | 97% |

CUP: cancer of unknown primary; NET: neuroendocrine tumor

Summaries of product characteristic were also used. There is some conflicting statement among the publications. When the information regarding the strength of inhibition/induction was available, it was reported in the table.
Table 4 Potential drug–drug interactions of supportive oncology care drugs [22, 23, 29, 43, 50–52]

| Classes               | Drugs               | CYP3A4 interactions | P-gp interactions | BCRP interaction | Protein binding |
|-----------------------|---------------------|---------------------|-------------------|------------------|-----------------|
| Corticoid             | Dexamethasone       | Strong inducer and substrate | No                | No               | 77%             |
|                       | Prednisolone        | Moderate inducer and substrate | Inhibitor and substrate | No              |                 |
| Bisphosphonates and Denosumab | Zoledronic acid | No                   | No                | No               | 33-40%          |
|                       | Pamidronic acid     | No                   | No                | No               | 54%             |
|                       | Ibandronic acid     | No                   | No                | No               | 87%             |
|                       | Denosumab           | No                   | No                | No               | No              |
| Antibiotics and antifungals | Fluconazol       | Strong CYP3A4 inhibitor | No                | No               | 11-12%          |
|                       | Itraconazol         | Strong CYP3A4 inhibitor | Inhibitor         | Inhibitor        | 99.8%           |
|                       | Clarithromycin      | Strong inhibitor and substrate | Substrate        | No               | 77%             |
|                       | Levofoxacin         | Moderate inhibitor and substrate | No              | No               | 30-40%          |
|                       | Doxycycline         | Moderate inhibitor and substrate | No              | No               | 82-93%          |
|                       | Erythromycin        | Strong inhibitor and substrate | Strong inhibitor and substrate | No             | No              |
|                       | Ondansetron         | Substrate            | Substrate        | No               | 70-76%          |
|                       | Palonosetron        | Substrate            | Substrate        | No               | 62%             |
|                       | Metoclopramide      | No                   | No                | No               | 97%             |
|                       | Aprepitant          | Moderate inhibitor and substrate | No              | No               |                 |
|                       | Fosaprepitant       | Moderate inhibitor and substrate | No              | No               | 97%             |
| Antiemetic drugs      | Oxycodone           | Substrate            | No                | No               | 38-45%          |
|                       | Hydromorphone       | No                   | No                | No               | <10%            |
|                       | Morphine            | No                   | No                | No               | 20-35%          |
|                       | Fentanyl            | Weak inhibitor and substrate | No              | No               | 80%             |
|                       | Methadone           | Weak inhibitor and substrate | No              | No               | 84-87%          |
|                       | Paracetamol         | Weak inhibitor and substrate | No              | No               | Low             |
| Analgesic and anxiolytic | Lorazepam         | No                   | No                | No               | 88-92%          |
|                       | Clonazepam          | Substrate            | No                | No               | 86%             |
|                       | Filgrastim          | No                   | No                | No               | No              |
|                       | Epoetin alfa/beta   | No                   | No                | No               | No              |
|                       | Darbepoetin alfa    | No                   | No                | No               | No              |
|                       | Leucovorin          | No                   | No                | No               | No              |

ESA: erythropoietin-stimulating agents; G-CSF: granulocyte colony-stimulating factor

There is some conflicting statement among the publications. When the information regarding the strength of inhibition/induction was available, it was reported in the table.
chemical agents such as cytotoxic chemotherapies or tyrosine kinase inhibitors. However, there are some exceptions, and monoclonal antibodies could also interact with CYP3A4. For example, brentuximab is a CYP3A4 substrate and a potential inhibitor of CYP3A4 [13, 47] (Tables 3 and 4). Brentuximab is an antibody-drug conjugate composed of the anti-CD30 chimeric monoclonal antibody and the potent antimicrotubule drug monomethylauristatin E (MMAE). This MMAE is a substrate of CYP3A4 and not the monoclonal antibody itself (SmPC, Adcetris®, EMA). Hence, it is essential to check for potential DDIs with the main compounds and the metabolites or "side" compounds and not automatically exclude a risk of DDIs because of the nature of a drug.

Guidelines, Algorithms, and Recommendations

The guidelines from international scientific societies highlight the importance of potential DDIs when choosing an anticoagulant [3–5] in CAT patients. Several publications follow an algorithm approach.

The American Society of Clinical Oncology (ASCO) [5] describes that one important safety consideration in using any DOACs in CAT patients is the potential for DDIs. Potent inhibitors/inducers of P-gp and potent inhibitors or inducers of CYP3A4 can interact with DOACs. The American Society of Hematology (ASH) states that the choice of anticoagulant treatment must be based on the specific clinical setting, including DDIs [4].

International Initiative on Thrombosis and Cancer (ITAC) also indicates that DOACs pose challenges in oral administration and DDIs [3].

Carrier M. et al. published the first CAT treatment algorithm [48]. This algorithm describes how to manage CAT and, more specifically, how to choose between LMWHs and DOACs. According to the treatment algorithm, patients considered to be at high risk of bleeding, those with active gastrointestinal or urothelial cancer, or those taking concomitant medications that would lead to potentially serious DDIs with DOACs should be treated with a therapeutic dose of extended-duration LMWHs. Later, two other algorithms [49, 50] also had very similar recommendations.

Terrier J. et al. [51] published a practical recommendation regarding the use of anticoagulants when facing potential DDIs, in non-cancer patients. Interestingly, in the case of moderate/weak P-gp inhibitor only, the authors recommend using DOACs with caution and weight benefit-risk ratio or consider VKAs as a first-line treatment if patients possess at least two risk factors. LMWHs were not mentioned, likely because Terrier J. et al. focused on non-cancer patients. The same recommendation was made in moderate/weak CYP3A4/5 inhibitor only for apixaban and rivaroxaban. Finally, in the case of CYP3A4/5 or combined Pgp/CYP3A4/5 inducer, co-administration is not recommended.

The indication of VKAs is also questionable. Indeed, guidelines are still giving some space for VKAs. The ASH CAT guidelines suggested to use low-dose acetylsalicylic acid or fixed low-dose VKA or LMWH for multiple myeloma patients receiving lenalidomide, thalidomide, or pomalidomide-based regimens [4]. The ASCO guidelines are also considering VKAs for the long-term anticoagulation if LMWHs or DOACs are not accessible. The same guideline is also stating that anticoagulation with LMWHs, DOACs, or VKAs beyond the initial 6 months should be offered to select patients with active cancer [5]. Finally, besides the fact that VKAs need a regular monitoring using INR, it could be a potential solution when adherence is challenging.

Conclusion

DDIs are associated with an increased risk of bleeding or recurrent VTE in patients with CAT. Moreover, the DDIs may reduce the efficacy and safety of anticancer therapies or other drugs used for concomitant medical conditions. The clinical evidence on the impact of DDIs in daily practice is minimal, particularly in patients with cancer.

The recent RCTs designed to compare the efficacy and safety of DOACs vs LMWHs in patients with CAT excluded those at risk of potential DDIs. Consequently, the available data are minimal and particular attention must be taken into account when prescribing anticoagulants in this setting. Further prospective research on this topic would be challenging from a practical and ethical point of view since it would expose patients to either bleeding risk (with inhibitors) or VTE recurrence (with inducers). Moreover, the DDIs could lead to a decrease in the efficacy of antineoplastic therapies. Consequently, the assessment of potential DDIs in patients with CAT is currently based on the empirical estimation according to the metabolic profile of each drug and data from case reports and retrospective studies. Thus, it is advisable to reassess periodically on changes in medications and the potential DDIs. The development of programs aimed at promoting the education and participation of patients to report changes in medications and eating habits or the use of herbal supplements would be of interest in this setting. Moreover, the implementation of automatic systems to cross data from the pharmacy and the clinicians involved in the care of patients in order to activate alerts for possible DDIs would be helpful.
Therefore, it is crucial to consider the regular review of potential DDIs when a new drug is introduced. This may be due to the change in cancer treatment or other cancer or non-cancer-related situations. A patient may face an infection during his treatment journey, and Hill [15] reported that antibiotics could negatively impact the outcomes in DDIs with DOACs. Therefore, it is crucial to consider the regular review of potential DDIs because the patient profile, cancer, comorbidities, and all the treatments evolve over time, highlighting the dynamic aspects of the diseases.

In conclusion, DDIs are a challenge in cancer patients and patients with CAT. More attention should be given to the recognition of potential drug–drug interactions in the initial anticoagulation management as well as in the anti-cancer treatment. Regular assessment of potential drug–drug interaction should be implemented, and therapies should be adapted according to the risk and the patients’ needs. Last but not least, we should keep in mind that drugs are treating a patient and not a disease, meaning that there is value when implementing a personalized approach. Inclusion of pharmacist on the treatment and oversight team and automated electronic drug interaction analysis is vital.

Authors contributions Nikolaos Tsoukalas has the idea and wrote, reviewed and coordinated the article, Norman Brito-Dellan wrote and reviewed the article, Carme Font wrote and reviewed the article, Taylor Butler reviewed the article, Cristhiam M. Rojas-Hernandez reviewed the article, and Carmen Escalante reviewed the article.

Funding None funding for this article.

Data availability Not applicable for this article

Code availability Not applicable for this article

Declarations

Conflicts of interest/Competing interests None conflicts of interest or competing interests to report

Ethics approval Not applicable for this article

Consent to participate Not applicable for this article

Consent for publication Not applicable for this article

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166: 458–464
2. Heit JA, Spencer FA, White RH (2016) The epidemiology of venous thromboembolism. J Thromb Thrombolysis 41:3–14
3. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounaumeaux H, Pabinger I, Douketis J (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20: e566–e581
4. Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5: 927–974
5. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JJ, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A (2020) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 38: 496–520
6. Gelosa P, Castiglioni L, Tencconi M, Baldessin L, Racagni G, Corsini A, Bellotta S (2018) Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 135: 60–79
7. Hussaarts K, Veerman GDM, Janssens FGA, van Gelder T, Mathijssen RHH, van Leeuwen RWF (2019) Clinically relevant drug interactions with multikinase inhibitors: a review. Ther Adv Med Oncol 11: 1758835918818347
8. Bteich M (2019) An overview of albumin and alpha-1-acid glycoprotein main characteristics: highlighting the roles of amino acids in binding kinetics and molecular interactions. Heliyon 5: e02879
9. Yamasaki K, Chuang VT, Maruyama T (2013) Otagiri M. Alummin-drug interaction and its clinical implication. Biochim Biophys Acta 1830:5435–5443
10. Dong Z, Li J, Wu F, Zhao P, Lee SC, Zhang L, Seo P, Zhang L (2020) Application of physiologically-based pharmacokinetic modeling to predict gastric pH-Dependent drug-drug interactions for weak base drugs. CPT Pharmacometrics Syst Pharmacol 9: 456–465
11. Patel SH, George TL, Wang TF, Vogt SM, Folefac E, Xu M, Yang Y, Parikh AB, Verschraegen CF, Clinton SK, Yin M (2021) Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low-molecular-weight heparin. Cancer 127: 938–945
12. Bellesoeur A, Thomas-Schoemann A, Allard M, Smadja D, Vidal M, Alexandre J, Goldwasser F, Blanchet B (2018) Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences. Crit Rev Oncol Hematol 129: 102–112

13. Short NJ, Connors JM (2014) New oral anticoagulants and the cancer patient. Oncologist 19: 82–93

14. Santini D, Citarella F, Vincenzi B, Russano M, Tonini G, Stelrato M (2019) Coboazantinib and apixaban: an hitherto unreported interaction. Exp Hematol Oncol 8: 22

15. Hill K, Sucha E, Rhodes E, Carrier M, Garg AX, Harel Z, Hundemer GL, Clark EG, Knoll M, McArthur E, Sood MM (2020) Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants. JAMA Intern Med

16. Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP (2020) The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding J Thromb Thrombolysis 49: 636–643

17. Holm J, Mannheimer B, Malmstrom RE, Ellisson E, Lindh JD (2021) Bleeding and thromboembolism due to drug–drug interactions with non-vitamin K antagonist oral anticoagulants—a Swedish, register-based cohort study in atrial fibrillation outpatients. Eur J Clin Pharmacol 77: 409–419

18. Wang TF, Baumann Kreuziger L, Leader A, Speert G, Lim MY, Gaahagan A, Gangaraju R, Sanfilippo KM, Mallick R, Zwicker JJ, Carrier M (2021) Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticoagulation therapies-TacDOAC registry; communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy. J Thromb Haemost 19: 2068–2081

19. Li A, Li MK, Crouther M, Vazquez SR (2020) Drug–drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review. Thromb Res 194: 240–245

20. Stollberger C (2017) Drug interactions with new oral anticoagulants in elderly patients. Expert Rev Clin Pharmacol 10: 1191–1202

21. Lakatos B, Stoeckle M, Elzi L, Battegay M, Marzolini C (2014) Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss Med Wkly 144: w13906

22. Serrao DA, Scalzulli DE, Brescia DM, Foa PR, Chistolloni PA (2020) Hemorrhagic complications in patients treated with azacitidine and direct oral anticoagulants. Am J Ther 1:1–2

23. Burden T, Thompson C, Bonanos E, Medford AR (2018) Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. Clin Med (Lond) 18: 103–105

24. (2021) Interactions médicamenteuses, cytochromes P450 et P-glycoprotéine (Pgp) https://www.hug.ch/sites/interrhub/files/structures/pharmacologie_et_toxicologie_cliniques/a5_cytoc hromes_6_2.pdf 17/03/2022

25. Hodin S, Basset T, Jacqueroux E, Delezay O, Cotlagatade A, Perek N, Mismatch P, Delavenne X (2018) In vitro comparison of the role of P-Glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition. Eur J Drug Metab Pharmacokinet 43: 183–191

26. Jacqueroux E, Mercier C, Margelidou-Cozzolino V, Hodin S, Bertolotti L, Delavenne V (2020) In vitro assessment of P-gp and BCRP transporter-mediated drug–drug interactions of doxicogut with direct oral anticoagulants. Fundam Clin Pharmacol 34:109–119

27. Sennesael AL, Dogne JM, Spinnewine A (2015) Optimizing the safe use of direct oral anticoagulants in older patients: a teachable moment. JAMA Intern Med 175: 1608–1609

28. Perlman A, Hochberg-Klein S, Choshen Cohen L, Dagan G, Hirsh-Raccah B, Horwitz E, Aldousby-Bier G, Negev T, Matok I, Azoulay L, Kalish Y, Muszkat M (2019) Management strategies of the interaction between direct oral anticoagulant and drug-metabolizing enzyme inducers. J Thromb Thrombolysis 47:590–595

29. De Simone G, Pasquadibisceglie A, di Masi A, Buzzelli V, Trezza V, Macari G, Politicelli F, Ascenzi P (2020) Binding of direct oral anticoagulants to the FA1 site of human serum albumin. J Mol Recognit: e2877

30. Beyer-Westendorf J, Klamroth R, Kreher S, Langer F, Matzdorf A, Riess H (2019) Non-vitamin K antagonist oral anticoagulants (NOAC) as an alternative treatment option in tumor-related venous thromboembolism. Dtsch Arztebl Int 116: 31–38

31. van Leeuwen RW, van Gelder T, Mathijssen RJH, Jansman FGA (2014) Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol 15: e315–e326

32. Janus N, Launay-Vacher V (2017) Pharmacokinetic/pharmacodynamic considerations for cancer patients undergoing hemodialysis. Expert Opin Drug Metab Toxicol 13:617–623

33. Verbeek RK, Musumaba FT (2009) Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65: 757–773

34. Di Minno A, Frigerio B, Spadarella G, Ravanì A, Sansoro D, Amato M, Kitzmiller JP, Pepi M, Tremoli E, Baldassarre D (2017) Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev 31:193–203

35. Tarr DM, Barrientos M, Wang AY, Ramaprasad A, Fang MC, Schwartz JB (2020) Prevalence and knowledge of potential interactions between over-the-counter products and apixaban. J Am Geriatr Soc 68: 155–162

36. Min JS, Bae SK (2017) Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling. Arch Pharm Res 40: 1356–1379

37. van Leeuwen RW, Brundel DH, Neef C, van Gelder T, Mathijssen RH, Burger DM, Jansman FG (2013) Prevalence of potential drug–drug interactions in cancer patients treated with oral anti-cancer drugs. Br J Cancer 108: 1071–1078

38. Lechat P, Bergmann JF, Hanon O, Beauvais F, Pol S, Cavagna F, Gareniaux M, Livet D, Sicard J, Véron F, DiMaria B, Launay Vacher V, Janus N, Deray G (2018) Qualitative and quantitative evaluation of the iatrogenic risk in elderly patients in the community: the iPOP study. Lettre du Pharmacologue 30: 76–82

39. Delafuente JC (2003) Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol 48:133–143

40. Nightingale G, Hajjar E, Swartz K, André-Sendecki J, Chapman A (2015) Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol 33:1453–1459

41. Martinez BK, Baker WL, Sood NA, Bunz TJ, Meinecke AK, Eriksson D, Coleman CI (2019) Influence of polypharmacy on the effectiveness and safety of Rivaroxaban versus Warfarin in patients with nonvalvular atrial fibrillation. Pharmacotherapy 39:196–203

42. Hoemme A, Barth H, Haschke M, Kranenbuhl S, Strasser F, Lehner C, von Kameke A, Walti T, Thürlimann B, Fruh M, Driessen C, Joerger M (2019) Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer. Cancer Chemother Pharmacol 83: 763–774

43. Sebuhyan M, Crichi B, Abdallah NA, Bonnet C, Deville L, Marijouce Z, Farge D (2020) Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. JMV-Journal de Médecine Vasculaire 45: 6S31–36S38

44. Greenblatt DJ, Patel M, Harmatz JS, Nicholson WT, Rubino CM, Chow CR (2018) Impaired rivaroxaban clearance in mild renal
insufficiency with verapamil coadministration: potential implications for bleeding risk and dose selection. J Clin Pharmacol 58: 533–540
45. Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, Wynendaele W, Canon JL, Lybaert W, Nortier J, Deray G, Wildiers H (2010) Cancer and renal insufficiency results of the BIRMA study. Br J Cancer 103: 1815–1821
46. Gong IY, Kim RB (2013) Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol 29:S24–S33
47. Chu G, Versteeg HH, Verschoor AJ, Trines SA, Hemels MEW, Ay C, Huisman MV, Klok FA (2019) Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology. Blood Rev 35: 59–67
48. Carrier M, Blais N, Crowther M, Kavan P, Le Gal G, Moodley O, Shivakumar S, Tagalakis V, Wu C, Lee AYY (2018) Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus. Curr Oncol 25: 329–337
49. Moik F, Pabinger I, Ay C (2020) How I treat cancer-associated thrombosis. ESMO Open 5: e000610
50. Pernod G, Joly M, Sonnet B (2020) Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient). JMV-Journal de Médecine Vascularaire 45: 6S17–16S23
51. Terrier J, Gaspar F, Fontana P, Youssef D, Reny JL, Csajka C, Samer CF (2021) Drug-drug interactions with direct oral anticoagulants: practical recommendations for clinicians. Am J Med 134:939–942
52. Fujita-Hamabe W, Nishida M, Nawa A, Kobori T, Nakamoto K, Kishioka S, Tokuyama S (2012) Etoposide modulates the effects of oral morphine analgesia by targeting the intestinal P-glycoprotein. J Pharm Pharmacol 64: 496–504

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.